-+ 0.00%
-+ 0.00%
-+ 0.00%

Austria's Marinomed Biotech to File for Court-led Restructuring

MT Newswires·07/17/2026 02:13:06
Listen to the news
02:13 AM EDT, 07/17/2026 (MT Newswires) -- Austrian biotech company Marinomed Biotech (MARI.VI) said Thursday it plans to file for court-supervised restructuring proceedings without self-administration. The company's court-approved restructuring plan from November 2024 collapsed after talks with Unither Pharmaceuticals broke down and Unither failed to make earn-out payments tied to the sale of Marinomed's Carragelose business unit, leaving the company at risk of insolvency. The new restructuring plan aims to restore the company's financial stability. The company added it is considering legal action against Unither over the sale of the Carragelose business and the Marinosolv platform assets.